Monoclonal Antibodies to Conformational Epitopes of the Surface Glycoprotein of Caprine Arthritis-Encephalitis Virus: Potential Application to Competitive-Inhibition Enzyme-Linked Immunosorbent Assay for Detecting Antibodies in Goat Sera

FUAT ÖZYÖRÜK,1 WILLIAM P. CHEEVERS,1 GORDON A. HULLINGER,1 TRAVIS C. McGUIRE,1 MELINDA HUTTON,1 AND DONALD P. KNOWLES1,2*

Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington 99164-7040,1 and Animal Disease Research Unit, Agricultural Research Service, U.S. Department of Agriculture, Pullman, Washington 99164-70302

Received 28 July 2000/Returned for modification 2 October 2000/Accepted 17 October 2000

Four immunoglobulin G1 monoclonal antibodies (MAbs) to the gp135 surface envelope glycoprotein (SU) of the 79–63 isolate of caprine arthritis-encephalitis virus (CAEV), referred to as CAEV-63, were characterized and evaluated for their ability to compete with antibody from CAEV-infected goats. Three murine MAbs (MAbs GPB16A, 29A, and 74A) and one caprine MAb (MAb F7-299) were examined. All MAbs reacted in nitrocellulose dot blots with native CAEV-63 SU purified by MAb F7-299 affinity chromatography, whereas none reacted with denatured and reduced SU. All MAbs reacted in Western blots with purified CAEV-63 SU or the SU component of whole-virus lysate following denaturation in the absence of reducing agent, indicating that intramolecular disulfide bonding was essential for epitope integrity. Peptide-N-glycosidase F digestion of SU abolished the reactivities of MAbs 74A and F7-299, whereas treatment of SU with N-acetylmuramidase glycohydrolase (sialidase A) under nonreducing conditions enhanced the reactivities of all MAbs as well as polyclonal goat sera. MAbs 29A and F7-299 were cross-reactive with the SU of an independent strain of CAEV (CAEV-Co). By enzyme-linked immunosorbent assay (ELISA), the reactivities of horseradish peroxidase (HRP)-conjugated MAbs 16A and 29A with homologous CAEV-63 SU were <10% of that of HRP-conjugated MAb 74A. The reactivity of HRP-conjugated MAb 74A was blocked by sera from goats immunized with CAEV-63 SU or infected with CAEV-63. The reactivity of MAb 74A was also blocked by sera from goats infected with a CAEV-Co molecular clone, although MAb 74A did not react with CAEV-Co SU in Western blots. Thus, goats infected with either CAEV-63 or CAEV-Co make antibodies that inhibit binding of MAb 74A to CAEV-63 SU. A competitive-inhibition ELISA based on displacement of MAb 74A reactivity has potential applicability for the serologic diagnosis of CAEV infection.

Caprine arthritis-encephalitis virus (CAEV), a monocyte/macrophage-tropic lentivirus, causes chronic progressive arthritis in up to 40% of domestic goats after a prolonged latent period (3, 14, 16, 17, 38). Transmission of CAEV occurs primarily by colostrum or milk from infected dams (2). The gp135 surface glycoprotein (SU), encoded by the CAEV env gene (29, 32), is the ligand for viral interaction with goat synovial membrane (GSM) cell receptors (21) and is a major target of macrophage-tropic infection, maturation of the antibody response toward increased recognition of conformational SU epitopes (J. D. Trujillo and W. P. Cheevers, unpublished data).

These observations suggest that a sensitive diagnostic test for CAEV infection could be based on strategies that enhance detection of antibodies to immunodominant conformational epitopes on SU that are cross-reactive among diverse CAEV strains. A broadly defined map of linear B-cell epitopes on CAEV SU and pepscan analysis of synthetic peptides have been completed (6, 49). However, the distribution of conformation-dependent B-cell epitopes is unknown. Accordingly, the present study reports (i) the derivation of four anti-CAEV SU monoclonal antibodies (MAbs) directed to conformational epitopes dependent on intramolecular disulfide bonding, (ii) evaluates the effects of glycosylation and sialylation on epitope exposure, and (iii) verifies that binding of one MAb is com-
petitively blocked by sera of goats infected with an independent CAEV strain.

MATERIALS AND METHODS

Caprine MAb F7-299 and affinity purification of native CAEV-63 SU. The derivation of anti-CAEV strain 79–63 (anti-CAEV-63) SU MAb F7-299 was described previously (39). Briefly, MAb F7-299 is secreted by a Xenohybridoma formed by fusion of murine X63-Ag8.6.5.3 myeloma cells with spleenocytes from a goat infected with the 79–63 isolate of CAEV (10, 14). The infected goat was immunized subcutaneously with adjuvant (RIBI, Hamilton, Mont.) containing recombinant CAEV SU derived from vaccinia virus rWR-63 expressing the CAEV-63 env gene (32) and was boosted intravenously with CAEV-63-infected GSM cells. MAb F7-299 from supernatants of triple cloned hybridoma cells was isoplated as immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) from supernatants of triple cloned hybridoma cells was isoplated as immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.). Native CAEV-63 SU was purified as a soluble 135-kDa glycoprotein from the medium of CAEV-63-infected GSM cells by affinity chromatography on CNBr-activated Sepharose 4B coupled with MAb immunoglobulin G1 (IgG1) by radial immunodiffusion, purified by chromatography on protein G agarose, and quantified with a bichinonic acid protein assay kit (Pierce, Rockford, Ill.).
CI-ELISA. On the basis of preliminary ELISA data, a competitive-inhibition ELISA (CI-ELISA) method was evaluated for detection and titration of anti-CAEV SU antibodies in goat sera by displacement of binding by HRP-conjugated MAb 74A. Each well of flat-bottom 96-well plates (Costar, Cambridge, Mass.) was coated overnight with 4.5 ng of MAb F7-299 in 50 μl of 100 mM carbonate buffer. The coated wells were blocked for 1 h with 100 mM NaH₂PO₄-Na₂HPO₄ buffer (pH 7.2) containing 0.75% glycine, 2% sucrose, 0.1% Tween 20, and 1% nonfat dry milk. After removal of blocking buffer, the wells were incubated overnight with 50 μl of CM to capture soluble SU. The plates were blocked again and were air dried for 48 h. The blocked wells were incubated for 1 h with 50 μl of undiluted goat serum or 50 μl of serum diluted in blocking buffer for end point titration. The wells were washed with PBS-Tween and were incubated for 30 min with HRP-conjugated MAb 74A and 20 min with tetramethylbenzidine substrate. Results were expressed as percent inhibition of MAb 74A binding calculated by 1 – (OD₅₇₀ for the sample)/OD₅₇₀ (for the plate control) × 100, where OD₅₇₀ is the optical density at 620 nm. End points for serum antibody titrations were extrapolated by linear regression analysis of percent inhibition plotted against serum dilutions and were defined relative to the background reactivity of the control sera on the plate.

RESULTS

Nitrocellulose dot blotting of affinity-purified native or denatured and reduced SU. The initial binding properties of the MAbs were determined by immunoblot analysis of native or denatured and reduced SU bound to nitrocellulose. The results are shown in Fig. 1. Murine MAbs 74A, 16A, and 29A as well as caprine MAb F7-299 reacted with native SU (data 1N, 2N, 3N, and 5N, respectively) but did not bind to denatured and reduced SU (data 1D, 2D, 3D, and 5D). Positive control serum from SU-immunized goat 9308 reacted with both native and denatured and reduced SU (lane 7), whereas SU was not reactive with negative control serum from uninfected goat 8505 (lane 6) or irrelevant isotype control MAb 79/17 (lane 4).

Western blotting of reduced or nonreduced SU. The data in Fig. 1 demonstrate that epitopes recognized by MAbs 74A, 16A, 29A, and F7-299 are dependent on the confirmation of native SU. Western blot analysis of MAbs with reduced and nonreduced SU was used to evaluate the dependence of epitope exposure on cysteine S-S bonding. An initial electrophoretic mobility assay with polyclonal goat serum 9308 was performed to confirm retention of S-S bonds following denaturation of SU glycoprotein with SDS without reduction by DTT. Compared to SU treated with 100 mM DTT in 2% SDS (Fig. 2A, lane 4), the mobility of SU progressively increased following denaturation in 2% SDS with 10 mM DTT (Fig. 2A, lane 3) or 100 mM DTT (Fig. 2A, lane 2), or no DTT (Fig. 2A, lane 1).

Western blots with anti-SU MAb used SU denatured in 2% SDS with or without 100 mM DTT. In these experiments, 100 mM IA was also included to stabilize reduced SH groups. All four MAbs reacted with nonreduced SU (Fig. 2B, lanes designated with minus signs), whereas none of the MAbs reacted with reduced SU (Fig. 2B, lanes designated with plus signs). Similar results were obtained with nonreduced SU denatured in 0.2% SDS (data not shown). Thus, Western blot analysis of MAb binding to reduced or nonreduced SU denatured with SDS demonstrated that epitopes recognized by MAbs are dependent on S-S bonding of SU cysteine residues and are not dependent on other structural properties of SU sensitive to denaturation by SDS.

Western blotting of SU treated with PNGase F under nonreducing conditions. The 550-amino-acid SU of CAEV-63 contains 23 potential N-linked glycosylation sites as well as 22 cysteine residues (29). To determine if N-glycans contribute to MAb epitopes or epitope exposure, PNGase F-digested SU was analyzed by Western blotting under nonreducing conditions. The extent of deglycosylation of SU by PNGase F was monitored independently by glycan staining. As expected from the data in Fig. 2B, all anti-SU MAbs as well as polyclonal serum from goat 9308 recognized mock-treated SU under nonreducing conditions (Fig. 3A, lanes 2, 4, 6, 8, and 14). SU was...
not reactive with isotype control MAb 79/17 (Fig. 3A, lane 10) or serum from uninfected goat 8505 (Fig. 3A, lane 12). PNGase F digestion for 16 h reduced the apparent molecular mass of SU from ~133 kDa (Fig. 3A, lane 14) to ~60 kDa (Fig. 3A, lane 13). This reduction in apparent molecular mass, accompanied by the loss of glycan staining (Fig. 3B, lanes 1 and 2), was consistent with complete removal of glycans (29). Anti-SU MAbs 16A and 29A reacted with deglycosylated SU (Fig. 3A, lanes 3 and 5), whereas deglycosylated SU did not bind to MAb 74A or F7-299 (Fig. 3A, lanes 1 and 7).

Western blotting of SU treated with sialidase A under nonreducing conditions. Sialic acid residues have been implicated in masking exposure of CAEV and HIV-1 SU epitopes (5, 22). To determine if sialic acids affect binding of anti-CAEV SU MAbs, SU was digested with sialidase A and analyzed by Western blotting under nonreducing conditions. Desialylation was monitored independently and confirmed that sialic acid residues were substantially digested by sialidase A (Fig. 4B, lanes 1 and 2). Desialylation of SU provided 1.8- to 4.7-fold enhanced reactivity of both MAbs and polyclonal antibodies with SU (Fig. 4A).

Cross-reactivity of anti-CAEV-63 SU MAbs with CAEV-Co SU. Western blots of MAbs 74A, 16A, 29A, and F7-299 against whole-virus lysates of homologous CAEV-63 and heterologous CAEV-Co are shown in Fig. 5. All four MAbs reacted specifically with CAEV-63 SU under nonreducing conditions (Fig. 5A, lanes designated with minus signs). MAb 29A cross-reacted with CAEV-Co SU, and MAb F7-299 was also weakly cross-reactive with CAEV-Co SU (Fig. 5B). However, MAbs 74A and 16A did not detectably react with CAEV-Co SU (Fig. 5B).

ELISA reactivity of HRP-conjugated MAbs with CAEV-63 SU. MAbs were evaluated for use in the development of a CI-ELISA for detection of anti-CAEV SU antibodies in goat sera. On the basis of the use of MAb F7-299 for affinity purification of SU, the ability of MAb F7-299-coated plates to capture SU was tested. As expected from immunoblotting results, HRP-conjugated MAb 74A reacted with SU incubated with MAb F7-299-coated wells (Fig. 6, open bar). In contrast, HRP-conjugated MAb 74A did not react with SU incubated with wells coated with MAb 16A and 29A (data not shown). In addition, the reactivities of HRP-conjugated MAbs 16A and 29A with SU bound to plates was ~10% of that of MAb 74A (data not shown).

Competitive binding of CAEV-63 SU by Mab and goat sera. The ability of goat sera to block the reactivity of MAb 74A with MAb F7-299-captured SU was evaluated by ELISA. Sera from uninfected goats (goats 9213, 9212, and 9136) did not compete with MAb 74A binding (Fig. 6A), whereas sera from CAEV-infected goats (goats 9111, 9128, and 9132) blocked MAb 74A reactivity with SU (Fig. 6A). Additional experiments demonstrated that MAb F7-299 was able to capture soluble SU from the CM of CAEV-63-infected GSM cells (Fig. 6B, open bar). MAb 74A reactivity with soluble SU was also blocked by sera from CAEV-infected goats (Fig. 6B, goats 9111, 9128, and 9132) but not by sera from uninfected goats (Fig. 6B, goats 9213, 9212, and 9136).

Titration of anti-CAEV SU antibodies in goat sera by CI-ELISA. As expected, the results in Fig. 6 demonstrated that serum from CAEV-63-infected goat 9111 blocked binding of the MAb 74A conjugate to CAEV-63 SU. However, sera from goats 9128 and 9132 infected with CAEV-Co also inhibited binding of MAb 74A (Fig. 6), although MAb 74A did not react with CAEV-Co SU in Western blots (Fig. 5). Sera from goats 9128 and 9132 were drawn 4 years after experimental infection with CAEV-Co. Thus, one explanation for the data in Fig. 6 is that CAEV variants in goats 9128 and 9132 acquired the MAb 74A epitope. To test this possibility, sera from four goats immunized with CAEV-63 SU and four goats infected with a CAEV-Co molecular clone were compared by CI-ELISA. To minimize the effect of antigenic variation of SU, sera from goats infected with the CAEV-Co clone were evaluated at 4
weeks postinfection (corresponding to a maximum of 2 weeks after initial seroconversion). As expected, sera from CAEV-63 SU-immunized goats displaced MAb 74A binding to CAEV-63 SU with end point titers of 28,000 (goat 9302), 41,500 (goat 9304), 32,500 (goat 9305), and 23,500 (goat 9308) (Fig. 7A). However, sera from goats infected with the CAEV-Co clone also inhibited MAb 74A binding to CAEV-63 SU with end point titers of 3,250 (goat 9905), 1,900 (goat 9907), 190 (goat 9908), and 235 (goat 9909) (Fig. 7B). To confirm the results in Fig. 6, serum anti-SU antibody titers were determined for two additional goats chronically infected with CAEV-63 or CAEV-Co. On the basis of linear regression analysis of the data in Fig. 7C, serum anti-SU antibody titers were 37,000 and 2,800 for CAEV-63-infected goats 8517 and 8528 respectively, at 7 years postinfection, 5,500 for CAEV-Co-infected goat 8935 at 1 year postinfection, and 955 for CAEV-Co-infected goat 8938 at 3 years postinfection. These results suggest that the MAb 74A epitope on CAEV-63 SU was blocked by anti-CAEV-Co SU antibodies directed against an overlapping epitope conserved between CAEV-63 and CAEV-Co SU.

**DISCUSSION**

CAEV SU is a complex virion surface glycoprotein that comprises 546 to 550 amino acids with 22 cysteine residues and 20 to 23 potential N-linked glycosylation sites (29, 43, 49–51). An apparent molecular mass of \(135\) kDa based on SDS-PAGE under denaturing and reducing conditions indicates that most if not all of the potential N-linked sites are glycosylated. Extensive glycosylation of SU is also indicated by the pronounced reduction of the molecular mass following metabolic inhibition of glycosylation (11) or enzymatic deglycosylation of purified SU, as reported here. S-S bonds decrease the accessibility of SDS, resulting in increased SDS-PAGE mobility of denatured, nonreduced proteins according to the number of cysteines and the sizes of the cysteine loops (8, 15). However, we noted minimal increases in SDS-PAGE mobility of SU denatured with SDS in the presence of 1 to 100 mM DTT. This effect is attributed to heavy glycosylation of CAEV SU (40). Similar results were noted for HIV-1 gp120 (12), which contains nine S-S bonds and 18 to 24 glycosylation sites that comprise \(50\%\) of the molecular mass (31).

On the basis of env gene sequencing, all 22 cysteines and \(80\%\) of the N-linked glycosylation sites are conserved among three North American isolates and four French isolates of CAEV (49). SU cysteines and potential N-linked glycosylation sites are also highly conserved between CAEV and ovine maedi-visna virus (4, 9, 29, 41–44, 46, 47, 49, 50). Knowledge of the antigenic structure of CAEV SU is essential for unde-
standing mechanisms of disease pathogenesis and development of vaccines and diagnostic assays. The present study examined selected properties of three murine MAbs (IgG1 MAbs 16A, 29A, and 74A) and one caprine MAb (IgG1 MAb F7-299) to the SU of CAEV-63.

To obtain an initial assessment of the SU epitopes recognized by these MAbs, binding studies were performed with native SU and denatured SU with or without reduction of S-S bonds. These results demonstrated that all MAbs recognized conformation-dependent epitopes maintained by cysteine S-S bonding and that MAb binding was not dependent on the structural features of SU sensitive to SDS denaturation. In this regard, the CAEV SU MAbs are similar to a class of neutralizing MAbs directed to conformational epitopes of HIV-1 gp120 (52, 53). However, in a preliminary experiment, none of the MAbs detectably neutralized 2 × 10^3 tissue culture infectious doses of homologous CAEV-63 (Trujillo and Cheevers, unpublished data).

To further characterize the S-S bond-dependent epitopes identified by MAbs, we evaluated the effect of SU glycosylation on MAb binding. The results demonstrated that MAb 74A and F7-299 epitopes are glycan dependent, whereas the MAb 16A and 29A epitopes are glycan-independent epitopes. Carbohydrate-dependent MAb 74A and F7-299 epitopes are spatially distinct, as shown by a lack of competitive inhibition of MAb 74A binding by MAb F7-299. In addition, MAb F7-299 differentially cross-reacts with the SU of an independent CAEV isolate (CAEV-Co). Glycan-independent epitopes recognized by MAbs 16A and 29A were distinguished by differential binding of MAb 29A to CAEV-Co SU. Thus, anti-CAEV SU MAbs identified four distinct conformational epitopes maintained by cysteine S-S bonds, two of which require glycosylation for MAb binding.

Binding of MAbs 74A and F7-299 was completely sensitive to deglycosylation of SU by PNGase F, whereas MAb 74A binding was differentially retained following partial deglycosylation of SU. Thus, different carbohydrate residues are involved in binding of MAbs 74A and F7-299. However, these studies do not establish the nature of these epitopes with regard to the role of glycans in MAb binding. Carbohydrates may be epitope components. Alternatively, MAb binding sites may be discontinuous peptidic epitopes, and conformational features of the SU imposed by nearby glycan residues are required for their exposure to antibody.

At least two HIV-1 gp120 epitopes, defined by MAbs CRA3 and 2G12, are similar to CAEV SU epitopes 74A and F7-299 (35, 48). A third HIV-1 MAb (MAb G3-4) was originally reported to have a dual requirement for intact S-S bonds and N-linked glycans on the basis of digestion of gp120 with endo-β-N-acetylglucosaminidase H (20); however, in subsequent studies, MAb G3-4 did not bind to an endo-β-N-acetylglucosaminidase H-digested V1-V2 fusion protein (52). In any case, studies based on removal of specific N-linked glycans by site-directed mutagenesis have localized the glycan components of CRA3 and 2G12 epitopes to glycosylation sites adjacent to cysteine residues (48, 52). CAEV epitopes 74A and F7-299 may be comparable to HIV-1 epitopes CRA3 and 2G12, since 7 of 22 CAEV-63 SU cysteine residues have ad-
with 106 50% tissue culture infectious doses of CAEV-63 (plate control infected with CAEV-63. Sera were assayed 7 years after oral inoculation with 105 50% tissue culture infectious doses of CAEV-Co clone. Sera were assayed 4 weeks after intravenous inoculation with 105 50% tissue culture infectious doses of CAEV-Co (plate control OD620 = 0.942). (A) Immunization with CAEV-63 SU. Sera were assayed 2 weeks after the fifth immunization of goats with affinity-purified CAEV-Co SU in saponin adjuvant (plate control OD620 = 0.942). (B) Sera infected with CAEV-Co clone. Sera were assayed 4 weeks after intravenous inoculation with 104 50% tissue culture infectious doses of a CAEV-Co molecular clone (controls: plate control OD620 = 0.992; preinfection sera [four goats] OD620 = 1.028 ± 0.066). (C) Sera infected with CAEV-63. Sera were assayed 7 years after oral inoculation with 106 50% tissue culture infectious doses of CAEV-63 (plate controls were serum 8517 [OD620 = 0.942] and serum 8528 [OD620 = 1.125]). Sera were also infected with CAEV-Co. Sera were assayed 1 year (goat 8935) or 3 years (goat 8938) after oral inoculation with 106 50% tissue culture infectious doses of CAEV-Co (plate control OD620 = 0.942).

FIG. 7. CI-ELISA reactivities of goat sera. Soluble SU released into the medium of CAEV-63-infected GSM cells was captured on Costar plates coated with MAb F7-299. The indicated dilutions of goat sera were reacted with captured SU and then with HRP-conjugated MAb 74A. Percent inhibition of MAb 74A binding was calculated with the equation 1 – [(OD620 for the sample/OD620 for the plate control)] × 100. (A) Immunization with CAEV-63 SU. (B) Sera infected with CAEV-Co clone. (C) Sera infected with CAEV-63 SU.

jacent N-linked glycosylation sites (29). It has been suggested that high-mannose carbohydrate is an integral component of the HIV-1 2G12 epitope (52) because MAb 2G12 is broadly cross-reactive with primary and T-cell-adapted viruses, despite the variability of the underlying protein surface (48). By this criterion, it seems unlikely that CAEV MAb 74A binds directly to carbohydrate, since it is not cross-reactive with heterologous CAEV-Co SU, which shares 22 of 23 potential N-linked glycosylation sites with CAEV-63 SU (29, 43). Thus, present data indicate that 74A is a discontinuous S-S bond-dependent peptide epitope whose exposure is influenced by adjacent or nearby glycans. However, the cross-reactivity of MAb F7-299 with CAEV-Co SU may indicate that this epitope has an integral carbohydrate component, in addition to a requirement for intact S-S bonds.

The negative charge of sialic acid as a terminal component of glycans inhibits intermolecular interactions (45) and shields exposure of CAEV SU neutralization epitopes (22) as well as cross-reactive epitopes on HIV-1 and HIV-2 (5). The present study confirmed that desialylation of CAEV SU under nonreducing conditions enhances the exposure of MAb epitopes evaluated by Western blotting and also demonstrated enhancement of polyclonal antibody reactivity with desialylated SU. On the basis of these findings, we suggest that desialylated antigen will improve the sensitivity of Western blot assays for detection of antibodies to lentiviral envelope proteins.

Sera from infected goats were evaluated for their ability to block binding of MAb to SU for possible use in a CI-ELISA for detection of anti-CAEV SU antibodies. On the basis of the MAb binding to SU bound directly or captured on microtiter plates with MAb F7-299, HRP-conjugated MAb 74A was selected for detailed studies. Inhibition of MAb 74A binding to CAEV-63 SU by sera from goats infected with molecularly cloned CAEV-Co demonstrated the potential utility of this assay for evaluation of field sera. Thus, the main outcome of this study with respect to diagnostics is that a CI-ELISA with MAb 74A may have diagnostic potential, especially when supplemented with a Western blot assay with desialylated nonreduced SU.

ACKNOWLEDGMENTS


This work was supported by grants from the National Institutes of Health (grants R01 AR43710 and R21 AI42690) and the Agricultural Research Service, U.S. Department of Agriculture (grant CWU S348-32000-015-00D). F. Özyörük thanks GDAR of the Turkish Ministry of Agricultural and Rural Affairs for scholarship support.

REFERENCES


